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In the 1980’s, isolated case reports appeared in the world
literature documenting patients who appeared to suffer
from an often fatal complication associated with the
demonstration of antiphospholipid antibodies (aPL). The
clinical picture comprised widespread multi-organ throm-
bosis and consequent organ failure and was referred to by
the authors as a “devastating non-inflammatory vasculo-
pathy”,"occlusive vasculopathy” or “acute disseminated
coagulopathy-vasculopathy” when describing individual
cases. In 1992, ten patients with this unusual condition
were first reviewed and, in an attempt to define its acute-
ness and severity, the eponym “catastrophic” was attached
to this variant of the antiphospholipid syndrome (APS).
Although less than 1% of patients with the APS develop
this complication, its potentially lethal outcome, despite all
recommended therapies, emphasizes its importance in
clinical medicine today. The majority of these patients end
up in Intensive Care Units (ICU) with multi-organ failure
and, unless the condition is considered in the differential
diagnosis by the attending physicians, it may be completely
missed with a disastrous outcome for the patients.
The rarity of the syndrome makes it extraordinarily diffi-
cult to study in any systematic way. In order to put
together all the published case reports as well as the new
diagnosed cases from all over the world, an International
Registry of patients with catastrophic APS was created in
2000 by the European Forum on Antiphospholipid Antibo-
dies ("CAPS Registry”). The initial results of the project
have been already presented in several original papers.
Currently, it documents the entire clinical, laboratory and
therapeutic data of more than 400 patients whose data has
been fully registered and it is expected that the periodical
analysis of these data will allow us to increase our knowl-
edge of this condition. The purpose of this presentation is
to focus on the current management of these patients and
some of the potential new therapeutic approaches.
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